Psilocybin for Depression: From Credibility to Feasibility, What's Missing?

Munafò, Antonio; Arillotta, Davide; Mannaioni, Guido; Schifano, Fabrizio; Bernardini, Renato; Cantarella, Giuseppina

Munafò, Antonio; Arillotta, Davide; Mannaioni, Guido; Schifano, Fabrizio; Bernardini, Renato; Cantarella, Giuseppina.

Afiliación

Munafò A; Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, 95123 Catania, Italy.
Arillotta D; Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Viale G. Pieraccini, 6, 50139 Florence, Italy.
Mannaioni G; Psychopharmacology, Drug Misuse & Novel Psychoactive Substances Research Unit, School of Life & Medical Sciences, University of Hertfordshire, Hertfordshire AL10 9EU, UK.
Schifano F; Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Viale G. Pieraccini, 6, 50139 Florence, Italy.
Bernardini R; Psychopharmacology, Drug Misuse & Novel Psychoactive Substances Research Unit, School of Life & Medical Sciences, University of Hertfordshire, Hertfordshire AL10 9EU, UK.
Cantarella G; Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, 95123 Catania, Italy.

Pharmaceuticals (Basel) ; 16(1)2022 Dec 31.

Article en En | MEDLINE | ID: mdl-36678564

Palabras clave

clinical trials; depression; ethical concerns; methodological issues; psilocybin

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Aspecto: Ethics Idioma: En Revista: Pharmaceuticals (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google